Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trans sodium crocetinate + temozolomide
- Development stage
- Phase 3
- Lead developer
- CervoMed
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Trans sodium crocetinate (TSC) + temozolomide is a combination therapy used primarily for the treatment of glioblastoma multiforme (GBM). TSC functions as an oxygen diffusion enhancer that improves oxygen delivery to hypoxic tissues, including cancerous tumors. By increasing oxygenation in tumor tissue, TSC potentially enhances the effectiveness of temozolomide and radiation therapy. Temozolomide is an alkylating agent that works by interfering with cancer cell DNA replication, preventing tumor growth. Clinical studies have shown that adding TSC to temozolomide and radiation therapy significantly improved survival rates and reduced tumor size compared to standard treatment alone.
- Other names
- temozolomide and trans sodium crocetinateTMZ + TSC
02
Targets
DNA
Beyond the preview
Go deeper on trans sodium crocetinate + temozolomide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trans sodium crocetinate + temozolomide.